The literature on inhibitors: Articles that influence my management of patients with hemophilia A and high-titer inhibitors

American Journal of Hematology

Volumn 87, Issue SUPPL. 1, 2012, Pages

  Leissinger, Cindy A ^a  

^a TULANE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATED PROTHROMBIN COMPLEX; BLOOD CLOTTING FACTOR 10; BLOOD CLOTTING FACTOR 7; BLOOD CLOTTING FACTOR 7A; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 8 ANTIBODY; BLOOD CLOTTING FACTOR 8 INHIBITOR; BLOOD CLOTTING FACTOR 9; PLACEBO; PROTHROMBIN; PROTHROMBIN COMPLEX; RECOMBINANT BLOOD CLOTTING FACTOR 7A;

ANTIBODY TITER; ARTICLE; BLEEDING; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG RESPONSE; DRUG TREATMENT FAILURE; GASTROINTESTINAL HEMORRHAGE; HEMARTHROSIS; HEMOPHILIA A; HEMOSTASIS; HUMAN; MONOTHERAPY; MUCOSAL BLEEDING; MUSCLE BLEEDING; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REPEATED DRUG DOSE; RISK ASSESSMENT; RISK FACTOR; SINGLE DRUG DOSE;

BLOOD COAGULATION FACTOR INHIBITORS; COAGULANTS; FACTOR VIII; FEMALE; HEMOPHILIA A; HEMORRHAGE; HUMANS; MALE;

EID: 84859967918     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.23191     Document Type: Article

References (39)

1. Lawrence JS, Johnson JB. The presence of a circulating anti-coagulant in a male member of a hemophiliac family. Trans Am Clin Climatol Assoc 1941; 57: 223-231.
2. Munro FL. Properties of an anticoagulant found in the blood of a hemophiliac. J Clin Invest 1946; 25: 422-427.
3. Craddock C, Lawrence JS. A report of the mechanism of the development and action of an anticoagulant in two cases. Blood 1947; 2: 505.
4. Negrier C, Goudemand J, Sultan Y, et al. Multicenter retrospective study on the utilization of FEIBA in France in patients with factor VIII and factor IX inhibitors. French FEIBA Study Group. Factor Eight Bypassing Activity. Thromb Haemost 1997; 77: 1113-1119.
5. Key NS, Aledort LM, Beardsley D, et al. Home treatment of mild to moderate bleeding episodes using recombinant factor VIIa (Novoseven) in haemophiliacs with inhibitors. Thromb Haemost 1998; 80: 912-918.
6. Konkle BA, Ebbesen LS, Erhardtsen E, et al. Randomized, prospective clinical trial of recombinant factor VIIa for secondary prophylaxis in hemophilia patients with inhibitors. J Thromb Haemost 2007; 5: 1904-1913.
7. Leissinger C, Gringeri A, Antmen B, et al. Anti-inhibitor coagulant complex prophylaxis in hemophilia with inhibitors. N Engl J Med 2011; 365: 1684-1692.
8. DiMichele DM, Kroner BL. The North American Immune Tolerance Registry: Practices, outcomes, outcome predictors. Thromb Haemost 2002; 87: 52-57.
9. Mariani G, Kroner B. International immune tolerance registry, 1997 update. Vox Sang 1999; 77: 25-27.
10. Oldenburg J, Pavlova A. Genetic risk factors for inhibitors to factors VIII and IX. Haemophilia 2006; 12: 15-22.
11. Gouw SC, van den Berg HM, le Cessie S, van der Bom JG. Treatment characteristics and the risk of inhibitor development: A multi-center cohort study among previously untreated patients with severe hemophilia A. J Thromb Haemost 2007; 5: 1383-1390.
12. Makris M. Management of excessive anticoagulation or bleeding. Semin Vasc Med 2003; 3: 279-284.
13. Pindur G, Morsdorf S. The use of prothrombin complex concentrates in the treatment of hemorrhages induced by oral anticoagulation. Thromb Res 1999; 95: S57-S61.
14. von Depka M. Managing acute bleeds in the patient with haemophilia and inhibitors: Options, efficacy and safety. Haemophilia 2005; 11: 18-23.
15. Kurczynski EM, Penner JA. Activated prothrombin concentrate for patients with factor VIII inhibitors. N Engl J Med 1974; 291: 164-167.
16. Buchanan GR, Kevy SV. Use of prothrombin complex concentrates in hemophiliacs with inhibitors: Clinical and laboratory studies. Pediatrics 1978; 62: 767-774.
17. Sjamsoedin LJM, Heijnen L, Mauser-Bunschoten EP, et al. The effect of activated prothrombin-complex concentrate (FEIBA) on joint and muscle bleeding in patients with hemophilia A and antibodies to factor VIII. A double-blind clinical trial. N Engl J Med 1981; 305: 717-721.
18. Hilgartner MW, Knatterud GL. The use of factor eight inhibitor by-passing activity (FEIBA immuno) product for treatment of bleeding episodes in hemophiliacs with inhibitors. Blood 1983; 61: 36-40.
19. Lusher JM, Spira J, Rodriguez D. A four-year update of safety and efficacy of an albumin-free formulated B-domain deleted factor VIIII (BBD rFVIII, rVIIISQ) in previously untreated severe hemophilia A patients. Thromb Haemost 1999; 82: 1493.
20. Lusher JM, Blatt PM, Penner JA, et al. Autoplex versus proplex: A controlled, double-blind study of effectiveness in acute hemarthroses in hemophiliacs with inhibitors to factor VIII. Blood 1983; 62: 1135-1138.
21. Seligsohn U, Kasper CK, Osterud B, Rapaport SI. Activated factor VII: Presence in factor IX concentrates and persistence in the circulation after infusion. Blood 1979; 53: 828-837.
22. Hedner U, Kisiel W. Use of human factor VIIa in the treatment of two hemophilia A patients with high-titer inhibitors. J Clin Invest 1983; 71: 1836-1841.
23. Hedner U, Glazer S, Pingel K, et al. Successful use of recombinant factor VIIa in patient with severe haemophilia A during synovectomy. Lancet 1988; 2: 1193.
24. Lusher JM, Roberts HR, Davignon G, et al. A randomized, double-blind comparison of two dosage levels of recombinant factor VIIa in the treatment of joint, muscle and mucocutaneous haemorrhages in persons with haemophilia A and B, with and without inhibitors. rFVIIa Study Group. Haemophilia 1998; 4: 790-798.
25. Shapiro AD, Gilchrist GS, Hoots WK, et al. Prospective, randomised trial of two doses of rFVIIa (NovoSeven) in haemophilia patients with inhibitors undergoing surgery. Thromb Haemost 1998; 80: 773-778.
26. FEIBA NF [package insert]. Westlake Village, CA: Baxter Healthcare Corporation; February 2011.
27. NovoSeven® RT [package insert]. Bagsvaerd, Denmark: Novo Nordisk AS. August 2010.
28. Astermark J, Donfield SM, DiMichele DM, et al., for the FENOC Study Group. A randomized comparison of bypassing agents in hemophilia complicated by an inhibitor: The FEIBA NovoSeven Comparative (FENOC) Study. Blood 2007; 109: 546-551.
29. Young G, Shafer FE, Rojas P, Seremetis S. Single 270 microg kg(-1)-dose rFVIIa vs. standard 90 μg kg(-1)-dose rFVIIa and APCC for home treatment of joint bleeds in haemophilia patients with inhibitors: A randomized comparison. Haemophilia 2008; 14: 287-294.
30. Schneiderman J, Rubin E, Nugent DJ, Young G. Sequential therapy with activated prothrombin complex concentrates and recombinant FVIIa in patients with severe haemophilia and inhibitors: Update of our previous experience. Haemophilia 2007; 13: 244-248.
31. Manco-Johnson MJ, Abshire TC, Shapiro AD, et al. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med 2007; 357: 535-544.
32. Gringeri A, Lundin B, von Mackensen S, et al. A randomized clinical trial of prophylaxis in children with hemophilia A (the ESPRIT Study). J Thromb Haemost 2011; 9: 700-710.
33. Hoots WK, Ebbesen LS, Konkle BA, et al. Secondary prophylaxis with recombinant activated factor VII improves health-related quality of life of haemophilia patients with inhibitors. Haemophilia 2008; 14: 466-475.
34. Brackmann HH, Gormsen J. Massive factor-VIII infusion in haemophiliac with factor-VIII inhibitor, high responder. Lancet 1977; 2: 933.
35. Ho AY, Height SE, Smith MP. Immune tolerance therapy for haemophilia. Drugs 2000; 60: 547-554.
36. DiMichele DM. Immune tolerance: Critical issues of factor dose, purity and treatment complications. Haemophilia 2006; 12: 81-86.
37. Hay C, DiMichele D. The principal results of the Internationalized Immune Tolerance Study: A randomized dose comparison. Blood 2011:Published online before print November 18, 2011.
38. Collins PW, Mathias M, Hanley J, et al. Rituximab and immune tolerance in severe hemophilia A: A consecutive national cohort. J Thromb Haemost 2009; 7: 787-794.
39. Gouw SC, van der Bom JG, Marijke van den Berg H. Treatment-related risk factors of inhibitor development in previously untreated patients with hemophilia A: The CANAL cohort study. Blood 2007; 109: 4648-4654.